Metastatic Renal Cell Cancer—Systemic Therapy
نویسندگان
چکیده
منابع مشابه
Sequential Therapy in Metastatic Renal Cell Carcinoma
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade. As the number of available agents, and related volume of research, has grown, it is increasingly complex to know how to optimally treat patients. The authors are practicing medical oncologists at the US Oncology Network, the largest community-based network of oncology providers in the country, a...
متن کاملMetastatic Renal cell Carcinoma Presenting as a clear-cell Tumor in Tongue: A Case Report
Introduction: Metastatic lesions of the oral cavity are extremely rare, accounting for approximately 1% of all malignant oral tumors. The most common primary sources of metastatic tumors in the oral region are, from the most to the least common, the breast, lung, kidney, bone, and colon. Renal cell carcinoma accounts for nearly 3% of all adult malignancies. It usually metastasizes to the lungs,...
متن کاملAxitinib in sequential therapy in metastatic renal cell carcinoma
Efficacy of new molecularly targeted drugs in the treatment of renal cell carcinoma (RCC), confirmed in clinical studies in relation to survival and prolongation of time to progression, has became a big chance for patients with metastatic renal cell cancer. Axitinib is a potent and selective receptor tyrosine kinase for vascular endothelial growth factor (VEGFR-1, -2, -3), platelet-derived grow...
متن کاملCombination therapy in patients with metastatic renal cell carcinoma.
BE At the 2007 American Society of Clinical Oncology meeting, Merchan and colleagues presented results from the phase I portion of a trial that aimed to determine the maximum tolerated dose and dose-limiting toxicity of the combination of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus (Torisel, Pfizer) and the anti-vascular endothelial growth factor (VEGF) monoclonal antibody b...
متن کاملSystemic Therapy for Metastatic Non-Clear Cell Renal Carcinoma
Renal cell carcinoma (RCC) comprises 2-3% of all malignancies. Approximately 90% of renal tumors are RCCs, and 15% of these are non-clear cell tumors, which include papillary, chromophobe, Bellini duct (collecting duct) and sarcomatoid tumors. Antiangiogenic agents (sorafenib, sunitinib, pazopanib, temsirolimus, or bevacizumab), have not been specifically evaluated in phase III trials in patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Surgical Oncology
سال: 2018
ISSN: 0975-7651,0976-6952
DOI: 10.1007/s13193-018-0721-2